Protein binding of clindamycin in sera of patients with AIDS

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 5, 1996, Pages 1134-1138

  Flaherty Jr , John F ^a   Gatti, Giorgio ^a   White, John ^a   Bubp, Jeff ^a   Borin, Marie ^b   Gambertoglio, John G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CLINDAMYCIN; FAMOTIDINE; IBUPROFEN; MEGESTROL; NAPROXEN; OROSOMUCOID; PENTAMIDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG PROTEIN BINDING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOXOPLASMA; TOXOPLASMOSIS;

EID: 0029868127     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.5.1134     Document Type: Article

References (21)

1. 1 acid glycoprotein J. Infect. Dis. 171:546-551.
2. 1-acid glycoprotein (AAG) levels, abstr. 108. In Program and abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D C.
3. Craig, W. A., and B. Suh. 1991. Protein binding and the antimicrobial effects. methods for the determination of protein binding, p. 367-402. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. Williams & Wilkins Co., Baltimore.
4. Dannemann, B., A. McCutchan, D. Israelski, D. Antoniskis, C. Leport, B. Luft, et al. 1992. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann. Intern. Med. 116:33-43.
5. Flaherty, J. F., L. C. Rodondi, B. J. Guglielmo, J. C. Fleishaker, R. J. Townsend, and J. G. Gambertoglio. 1988 Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens. Antimicrob. Agents Chemother. 32:1825-1829.
6. Gatti, G., J. Flaherty, J. Bubp, J. White, M. Borin, and J. Gambertoglio. 1993. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob. Agents Chemother. 37:1137-1143.
7. Gordon, R. C., C. Regamey, and W. M. M. Kirby. 1973. Serum protein binding of erythromycin, lincomycin, and clindamycin. J. Pharm. Sci 62: 1074-1077.
8. Jeevendra Martin, J. A., D. R. Abernathy, and D. J. Greenblatt. 1984. Plasma protein binding of drugs after severe burn injury. Clin. Pharmacol Ther. 35: 535-539.
9. Joshi, A. M., and R. M. Stein. 1974. Altered serum clearance of intravenously administered clindamycin phosphate in patients with uremia J. Clin Pharmacol. 14:140-144.
10. 1 acid glycoprotein concentrations Pharmacotherapy 12:50-55.
11. Kremer, J. M. H., J. Wilting, and L. H. M. Janssen. 1988. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev. 40: 1-47.
12. Lee, B. L., D. Wong, N. L. Benowitz, and P. M. Sullam. 1993 Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin. Pharmacol. Ther. 53:529-535.
13. Leigh, D. A. 1981. Antibacterial activity and pharmacokinetics of clindamycin. J. Antimicrob. Chemother. 7(Suppl. A):3-9.
14. Luft, B. J., R. Hafner, A. H. Korzun, C. Leport, D. Antoniskis, E. M. Bosler, T. Bourland, et al. 1993. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 329:995-1000.
15. 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine. J. Acquired Immune Defic Syndr. 6:531-533.
16. Peddie, B. A., E. Dann, and R. R. Bailey. 1975. The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin. Aust. N. Z. J. Med 5:198-202
17. Suh, B. W. A., W. A. Craig, A. C. England, and R. L. Elliott. 1981. Effect of free fatty acids on protein binding of antimicrobial agents. J. Infect. Dis. 143:609-616.
18. Toma, E., S. Fournier, M. Dumont, P. Bolduc, and H. Deschamps. 1993 Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS, a randomized, double-blind pilot trial. Clin Infect. Dis. 17:178-184.
19. Voulgari, F., P. Cummins, T. Gardecki, N. J. Beeching, P. C. W. Stone, and J. Stuart. 1982. Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery, and infection. Br. Heart J. 48:352-356.
20. White, R. L., L. V. Friedrich, A. Z. Ables, and D. S. Burgess. Effect of elevated alpha-1 acid glycoprotein concentrations on serum protein binding of azithromycin. Pharmacotherapy, in press.
21. Williams, D. N., K. Crossley, C. Hoffman, and L. D. Sabath. 1975. Parenteral clindamycin phosphate: pharmacology with normal and abnormal liver function and effect on nasal staphylococci. Antimicrob. Agents Chemother 7: 153-158